Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Alzheimer Disease × birtamimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Immunoglobulin Light-chain Amyloidosis 3 Paraproteinemias 1 Amyloidosis 1 Alzheimer Disease 1

Interventions

XENP 1595 2 Dexamethasone 2 pomalidomide 1 birtamimab 1 Melphalan 1 Calcium Dobesilate 1 Bortezomib 1 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02632786 2019-04-05

PRONTO

Prothena Biosciences Ltd.

Phase 2 Completed

129 enrolled 18 charts

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡